Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes

What Was Tested

Researchers studied Insulin Aspart and Insulin Lispro in this randomized controlled trial publication.

Persistent glucose variability is a frequent condition in type 1 diabetes.

Continuous subcutaneous insulin infusion (CSII) is a rational option to overcome this clinical issue; however, no comparative studies have been reported for aspart and lispro insulin when used in CSII.

Who Took Part

The study group was 17 patients.

This single-center, randomized, controlled, 3-day crossover trial included 17 patients with type 1 diabetes.

Patients were randomized to receive insulin aspart or insulin lispro.

How the Study Was Run

The researchers set it up as a randomized and crossover study.

Random assignment meant chance, not the researchers, decided who got Insulin Aspart and who got the comparison, which limits bias.

In the crossover set-up each of the patients took both Insulin Aspart and the comparison in turn, acting as their own control.

The next day, they received a standard meal at breakfast and lunch and a bolus of insulin aspart or lispro based on insulin:carbohydrate ratio.

Patients were monitored for 8 h, after which they received a crossover treatment with insulin aspart or insulin lispro followed by the same procedure as previously.

What Was Measured

This study compare the effects of aspart and lispro delivered by CSII on glycemic stability as measured using a continuous glucose monitoring system.

PubMed files the paper under topics including Area Under Curve, Blood Glucose, Diabetes Mellitus, Type 1, Eating, Infusions, Subcutaneous, Insulin and Insulin Aspart.

What This Means in Plain Language

The paper is a randomized and crossover study of Insulin Aspart and Insulin Lispro in 17 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2008 (Diabetes technology & therapeutics), a journal based in United States.

More context: the Insulin Aspart compound page and the Insulin Lispro compound page, all human trials.